IP Library Granted Patent US 11,617,772
Granted Patent B2
US 11,617,772 · App. 16/566,150 · Granted Apr 4, 2023

Nutritional supplements and therapeutic compositions comprising probiotics

Inventors: Natalie Jones (Charlotte, NC); Mikala Hukka (Charlotte, NC)
Assignee: Direct Digital LLC
A61K35/747A23L33/105A23L33/135A23L33/175A61K31/197A61K31/20A61K31/4045A61K35/745A61K36/84A61K47/02A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,617,772
App. No.
16/566,150
Granted
Apr 4, 2023
Kind
B2
Abstract

Disclosed herein are therapeutic compositions and nutritional supplements comprising probiotic mixtures and sleep-support ingredients, and a method of treating digestive discomfort and sleep problems comprising administering an effective amount of a therapeutic composition comprising a probiotic component and a sleep support component. According to embodiments, therapeutic compositions for improved digestion are provided comprising: a probiotic component, comprising: at least one of Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium animalis, Lactobacillus rhamnosus , and Lactobacilus paracasei ; and a sleep support component, comprising: at least one of gamma-aminobutyric acid (GABA), valerian root extract, and melatonin. The therapeutic compositions are effective in treating both sleep disorders and digestive discomfort.

Claims (96)

1. A therapeutic composition for improving digestion consisting of:

a probiotic component consisting of:

Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium animalis, Lactobacillus rhamnosus , and Lactobacilus paracasei;

a sleep support component consisting of:

gamma-aminobutyric acid (GABA), valerian root extract, and melatonin; and

one or more excipients.

2. The therapeutic composition according to claim 1 , wherein the excipient is at least one of microcrystalline cellulose, silica, magnesium stearate, or a combination thereof.

3. The therapeutic composition of claim 1 , wherein the excipient consists of:

microcrystalline cellulose,

silica, and

magnesium stearate.

4. The therapeutic composition of claim 1 , consisting of:

at least 0.05 B CFU/g of the probiotic component,

at least 10 mg of gamma-aminobutyric acid (GABA),

at least 1 mg of valerian root extract, and

at least 0.1 mg of melatonin; and

one or more excipients.

5. The therapeutic composition of claim 1 , consisting of:

from about 0.05 B CFU/g to about 50 B CFU/g of the probiotic component,

from about 10 mg to about 500 mg of gamma-aminobutyric acid (GABA),

from about 1 mg to about 200 mg of valerian root extract,

from about 0.1 mg to about 10 mg of melatonin; and

one or more excipients.

6. The therapeutic composition of claim 1 , consisting of:

about 27 B CFU/g of the probiotic component,

about 100 mg of gamma-aminobutyric acid (GABA),

about 50 mg of valerian root extract,

about 1.50 mg of melatonin; and

one or more excipients.

7. The composition of claim 1 in a capsule.

8. A composition for improving digestion consisting of:

a culture blend consisting of:

Lactobacillus acidophilus (ATCC SD6865),

Lactobacillus acidophilus (ATCC SD6866),

Bifidobacterium bifidum (ATCC SD6869), and

Bifidobacterium animalis subsp. lactis (ATCC SD6870);

a microbiome blend consisting of:

Lactobacillus rhamnosus (IMC 501), and

Lactobacillus paracasei (IMC 502);

gamma-aminobutyric acid (GABA);

valerian root extract;

melatonin; and

one or more excipients.

9. The composition of claim 8 , wherein the one or more excipients consists of:

microcrystalline cellulose,

silica, and

magnesium stearate.

10. The composition of claim 8 , consisting of:

at least 1 B CFU/g of the culture blend,

at least 0.1 B CFU/g of the microbiome blend,

at least 10 mg of gamma-aminobutyric acid (GABA),

at least 1 mg of valerian root extract,

at least 0.2 mg melatonin, and

one or more excipients.

11. The composition of claim 8 , consisting of:

from about 1 B CFU/g to about 50 B CFU/g of the culture blend,

from about 0.1 B CFU/g to about 5 B CFU/g of the microbiome blend,

from about 10 mg to about 500 mg of the gamma-aminobutyric acid (GABA),

from about 1 mg to about 200 mg of the valerian root extract,

from about 0.1 mg to about 10 mg of melatonin; and

one or more excipients.

12. The composition of claim 11 , consisting of:

about 26 B B CFU/g of the culture blend,

about 1 B CFU/g of the microbiome blend,

about 100 mg of the gamma-aminobutyric acid (GABA),

about 50 mg of the valerian root extract,

about 01.50 mg of melatonin; and

one or more excipients.

13. The composition of claim 12 , further comprising wherein the one or more excipients consists of:

about 39 mg microcrystalline cellulose,

about 6 mg silica, and

about 4 mg magnesium stearate.

14. A method for improving digestion, comprising administering to an individual an effective dose of a composition consisting of:

Lactobacillus acidophilus,

Bifidobacterium bifidum,

Bifidobacterium animalis subsp. lactis,

Lactobacillus rhamnosus,

Lactobacillus paracasei,

gamma-aminobutyric acid (GABA),

valerian root extract,

melatonin; and

one or more excipients.

15. The method of claim 14 , wherein the composition promotes sleep.

16. The method of claim 14 , wherein the composition consists of:

about 26 B CFU/g of a culture blend consisting of:

Lactobacillus acidophilus (ATCC SD6865),

Lactobacillus acidophilus (ATCC SD6866),

Bifidobacterium bifidum (ATCC SD6869), and

Bifidobacterium animalis subsp. lactis (ATCC SD6870);

about 1 B CFU/g of a microbiome blend consisting of:

Lactobacillus rhamnosus (IMC 501), and

Lactobacillus paracasei (IMC 502);

about 100 mg of the gamma-aminobutyric acid (GABA);

about 50 mg of the valerian root extract;

about 1.50 mg of melatonin; and

one or more excipients.

Assignments (9)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL FOR REEL/FRAME 055998/0709 Recorded Feb 24, 2025
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS ADMINISTRATIVE AGENT
To: DIRECT DIGITAL, LLC
Reel/Frame 071015/0315 →
PATENT SECURITY AGREEMENT (THIRD PRIORITY) Recorded Dec 24, 2024
From: ANCIENT BRANDS, LLC; DIRECT DIGITAL, LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 069766/0496 →
PATENT SECURITY AGREEMENT (SECOND PRIORITY) Recorded Dec 24, 2024
From: ANCIENT BRANDS, LLC; DIRECT DIGITAL, LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS ADMINISTRATIVE AGENT.
Reel/Frame 069766/0504 →
PATENT SECURITY AGREEMENT (FIRST PRIORITY) Recorded Dec 24, 2024
From: ANCIENT BRANDS, LLC; DIRECT DIGITAL, LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS ADMINISTRATIVE AGENT.
Reel/Frame 069766/0439 →
RELEASE OF SECURITY INTEREST Recorded Apr 22, 2021
From: TRUIST BANK
To: DIRECT DIGITAL, LLC
Reel/Frame 056012/0043 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded Apr 21, 2021
From: DIRECT DIGITAL, LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS FIRST LIEN ADMINISTRATIVE AGENT
Reel/Frame 055989/0285 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Apr 21, 2021
From: KNS ACQUISITION CORP.; DIRECT DIGITAL, LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 055998/0709 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded May 18, 2020
From: DIRECT DIGITAL, LLC
To: TRUIST BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 052692/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2019
From: JONES, NATALIE; HUKKA, MIKALA
To: DIRECT DIGITAL, LLC DBA ADAPTIVE HEALTH
Reel/Frame 050413/0095 →
Continuity (2)
Provisional Application 62729811 · Sep 11, 2018
Related Publication 20200078421A1 · Mar 12, 2020